SCHEMBL15466808

SCHEMBL15466808

O=C(NC1(c2ccccc2)CCOc2cccnc21)c1ccc(F)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPM8 Q7Z2W7 1/20 0.54
KMT2A Q03164 4/20 0.37
MEN1 O00255 3/20 0.37
ALDH1A1 P00352 4/20 0.37
KDM4E B2RXH2 2/20 0.37
RAB9A P51151 7/20 0.36
NPC1 O15118 4/20 0.36
PLD2 O14939 1/20 0.36
PLD1 Q13393 1/20 0.36
AGTR1 P30556 1/20 0.36
HTT P42858 2/20 0.36
SMN1; SMN2 Q16637 3/20 0.35
PKM P14618 1/20 0.35
MAOB P27338 1/20 0.35
LMNA P02545 3/20 0.35
TDP1 Q9NUW8 2/20 0.35
MAPT P10636 1/20 0.35
CYP11B1 P15538 1/20 0.34
CYP11B2 P19099 1/20 0.34
THRB P10828 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15467106 0.96 TRPM8 (0.54) TRPM8KMT2AMEN1ALDH1A1KDM4E
SCHEMBL15467108 0.96 TRPM8 (0.54) TRPM8KMT2AMEN1ALDH1A1KDM4E
SCHEMBL16413753 0.94 TRPM8 (0.53) TRPM8KMT2AMEN1ALDH1A1KDM4E
SCHEMBL15567528 0.94 TRPM8 (0.53) TRPM8KMT2AMEN1ALDH1A1KDM4E
SCHEMBL16413757 0.94 TRPM8 (0.53) TRPM8KMT2AMEN1ALDH1A1KDM4E
SCHEMBL16413959 0.93 TRPM8 (0.56) TRPM8KMT2AMEN1RAB9ANPC1
SCHEMBL16413960 0.93 TRPM8 (0.56) TRPM8KMT2AMEN1RAB9ANPC1
SCHEMBL15467040 0.92 TRPM8 (0.54) TRPM8KMT2AMEN1ALDH1A1RAB9A
SCHEMBL15469370 0.92 TRPM8 (0.55) TRPM8KMT2AKDM4ERAB9ANPC1
SCHEMBL15566928 0.91 TRPM8 (0.54) TRPM8KMT2AMEN1ALDH1A1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8952009-B2 Chroman derivatives as TRPM8 inhibitors AMGEN INC. (US) 2015-02-10 US claimed
US-20140045855-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS AMGEN INC. (US) 2014-02-13 US claimed
WO-2014025651-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS AMGEN INC. (US) 2014-02-13 WO claimed
US-8952009-B2 Chroman derivatives as TRPM8 inhibitors AMGEN INC. (US) 2015-02-10 US disclosed
US-8952009-B2 Chroman derivatives as TRPM8 inhibitors AMGEN INC. (US) 2015-02-10 US disclosed
US-8952009-B2 Chroman derivatives as TRPM8 inhibitors AMGEN INC. (US) 2015-02-10 US disclosed
US-20150031668-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS AMGEN INC (US) 2015-01-29 US disclosed
US-20150031668-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS AMGEN INC (US) 2015-01-29 US disclosed
US-20150031668-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS AMGEN INC (US) 2015-01-29 US disclosed
US-20140045855-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS AMGEN INC. (US) 2014-02-13 US disclosed
US-20140045855-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS AMGEN INC. (US) 2014-02-13 US disclosed
WO-2014025651-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS AMGEN INC. (US) 2014-02-13 WO disclosed
US-20140045855-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS AMGEN INC. (US) 2014-02-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150031668-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS TRPM8, TRPM5, TRPM7 TRPM8 1/4885KMT2A 2639/4885MEN1 243/4885
US-20140045855-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS TRPM8, TRPM5, TRPM7 TRPM8 1/4885KMT2A 2639/4885MEN1 243/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.